The spirit of our founders: The values and mindsets that created Novo Nordisk a century ago

(24:15)

Novo Nordisk and Eli Lilly will dominate the obesity drug market long-term, says Mizuho's Jared Holz

(2:53)

How a new Denmark tariff could impact Novo Nordisk

(2:49)

Plus grosse entreprise d’Europe et pourtant méconnue: Novo Nordisk

(13:17)

Novo Nordisk Selloff Is an Overreaction, Barclays' Field Says

(4:35)

CagriSema still keeps the Novo Nordisk story in tact, says Barclays' Emily Field

(4:8)

Novo Nordisk: Why the stock of the Danish pharmaceutical giant is plunging

(4:8)

How to use NovoPen 4

(6:46)

Novo Nordisk is 'losing its pep' in GLP-1 race: BMO analyst

(6:22)

How Ozempic And Wegovy Accidentally Made Novo Nordisk A $400B Company

(19:20)

Novo Nordisk (Ozempic)

(3:45:26)

AG Keith Ellison settlement with Novo Nordisk over insulin pricing [RAW]

(23:9)

NBC News Exclusive: Ozempic and Wegovy Novo Nordisk CEO speaks out on high prices, drug shortages

(4:29)

How Novo Nordisk built an empire selling diabetes and weight-loss drugs

(2:16)

Novo Nordisk plunges after obesity drug trial disappoints | REUTERS

(1:31)

Novo Nordisk CEO defends high price off Ozempic and Wegovy

(5:)

BMO’s Evan David Seigerman cuts Novo Nordisk price target after Cagrisema data disappoints

(4:1econd)

Novo Nordisk CEO testifies before Senate on weight loss drug prices

(1:55)

Novo Nordisk shares sink on medicare price negotiation fears

(4:35)